In 2020, Evolva expects consistent product related revenue growth across business segments, and a decline in R&D revenue following the completion of the contract with BARDA. As product related-revenue becomes the main driver to the top line, EBITDA is expected to remain broadly at around prior-year level. The above outlook excludes any impact on Evolva's business from Coronavirus (COVID-19) which cannot be estimated at this point in time.